The article focuses on a warning issued by the U.S. Food and Drug Administration (FDA) on the link between sodium-glucose cotransporter 2 (SGLT-2) inhibitors and Fournier gangrene based on 12 cases of the rare infection that were identified between March 2013 and May 2018.